J.P. Morgan Notebook Day 1: PCSK9 Face-Off, Teva’s Slowed Growth, Merck’s Keytruda Wins, Lilly’s CDK4/6 Hopes And More
Daily round-up of news and notes from the 2017 J.P. Morgan Healthcare conference in San Francisco. Regeneron CEO rebuffs Amgen’s patent battle strategy; Teva CEO apologizes for reduced financial guidance; Merck looks for more Keytruda wins, combos; Lilly awaits potentially differentiating Phase III CDK4/6 data; Alkermes readies ALKS 5461 depression submission; Biden discusses cancer moonshot; FDA’s real world evidence views; and UniQure turns a corner.
You may also be interested in...
The immuno-oncology highlight of the upcoming American Society of Clinical Oncology annual meeting will be clinical data for Incyte's epacadostat with Merck's Keytruda as well as data with Bristol's Opdivo.
IDO has emerged at the lead suitor among new cancer immunotherapy targets to partner with PD-1/L1 inhibitors; the early data help show why big pharmas are so much on board.
NewLink is hoping FDA will accept its plans to run one Phase III registrational study of its IDO pathway inhibitor indoximod with an anti-PD-1 agent in frontline melanoma; Incyte updates its Phase III plans for epacadostat.